Clinical Trials

Therapeutic Area: Cancer

Phase 1 Clinical Trial

Status: Completed

MPC-3100 is a potent small-molecule orally bioavailable Hsp90 inhibitor that has been studied in a Phase 1 clinical trial to investigate the safety, tolerability and pharmacokinetics of MPC-3100. 

Data from this study were presented at the AACR-NCI-EORTC International Conference in November, 2011.  View Poster 

Visit clinicaltrials.gov for more information: http://www.clinicaltrials.gov/ct2/show/NCT00920205

Contact Us: clinical.trials@myrexis.com